• 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 36 Fair Values set on narratives written by author

RMDA Share Price Performance

ج.م5.06
1.65 (48.18%)
ج.م5.06
1.65 (48.18%)
Price ج.م5.06

RMDA Community Narratives

There are no narratives available yet.

Trending Discussion

Updated Narratives

No recently updated narratives available.

Snowflake Analysis

High growth potential with low risk.

2 Risks
1 Reward

Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) (S.A.E) Key Details

ج.م4.3b

Revenue

ج.م2.2b

Cost of Revenue

ج.م2.1b

Gross Profit

ج.م1.8b

Other Expenses

ج.م289.1m

Earnings

Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
n/a
0.14
49.01%
6.73%
95.7%
View Full Analysis

About RMDA

Founded
1986
Employees
n/a
CEO
Amr Morsy
WebsiteView website
ramedapharma.com

Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) (S.A.E), together with its subsidiaries, engages in producing, marketing, selling, and storing pharmaceutical reagents for human and veterinary use. It is also involved in producing, marketing, selling, and storing diagnostic reagents for individuals, laboratories, and hospitals; importing pharmaceutical reagents and raw materials; producing pharmaceutical reagents for human, veterinary, and diagnostic use; and producing food supplements for human use. The company was incorporated in 1986 and is based in 6th of October City, Egypt.

Recent RMDA News & Updates

Recent updates

No updates

Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) (S.A.E) Competitors